Patent SG-11201906543R-A (SG)
Title: HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
Inventor: VESCI LOREDANA
IPC: A61P31/18
Filed: 2018-03-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ill Hu onion I iolo DID MINH 100 110 1110 011 (10) International Publication Number WO 2018/178060 Al 04 October 2018 (04.10.2018) W I PO I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, A61K 47/68 (2017.01) A61P 31/18 (2006.01) KM, ML, MR, NE, SN, TD, TG). A61P 35/00 (2006.01) (21) International Application Number: (22) International Filing Date: PCT/EP2018/057744 Published: — with international search report (Art. 21(3)) — with amended claims (Art. 190)) 27 March 2018 (27.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17163065.0 27 March 2017 (27.03.2017) EP (71) Applicant: ALFASIGMA S.P.A. [IT/IT]; Via Ragazzi del '99 n. 5, 40133 Bologna (IT). (72) Inventors: VESCI, Loredana; Via Piero Gherardi 20, 00125 Roma (IT). DE SANTIS, Rita; Via Anchise 103, 00040 Pomezia (RM) (IT). MILAZZO, Ferdinan- do Maria; Via Chiusi 11, 00139 Roma (IT). GIANNINI, Giuseppe; Via Boezio 46/B, 00071 Pomezia (RM) (IT). TADDEI, Maurizio; Via Uopini 58, Monteriggioni, 53035 Monteriggioni, Siena (IT). FALTONI, Valentina; Via Sal- vo D'Acquisto 10°, 52048 Monte San Savino (AR) (IT). PETRICCI, Elena; Strada del Petriccio e Belriguardo 82, 53100 Siena (IT). (74) Agent: HIEBL, Inge; Kraus & Weisert, Patentanwalte PartGmbB, Thomas-Wimmer-Ring 15, 80539 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 1-1 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, • EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, O 00 N 1-1 (54) Title: HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY (57) : The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)- based antibody drug conjugates partic- O ularly with antibodies directed to ErbB 1, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well \" as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms 0 can be effective for therapeutic interventions.